CURAVAC

CuraVac is raising funds to finalize the product development of CV-MG01 and launch its breakthrough Targeted Active Therapy (TAT) to dogs suffering from Canine Myasthenia Gravis—a crucial step toward developing novel, durable treatments to address autoimmune diseases in both animals and humans.

Offering

  • Issuer: CURAVAC Europe NV/SA
  • Country: BE
  • Platform: Spreds
  • DD workflow status: Open due diligence
  • Added to CrowdDiligence: 2026-11-03
  • Last updated: 2026-11-03

Due-diligence status

This project is part of the CrowdDiligence due-diligence workflow. Detailed analysis is not publicly available on this page.

Read how CrowdDiligence works and about the platform for the methodology and editorial-independence statement.